欧林生物：2025年度净利润2,223.17万元，同比增长7.10%

Core Viewpoint - Olin Bio (688319.SH) reported a revenue of 704 million yuan for the fiscal year 2025, marking a year-on-year growth of 19.58% [1] - The net profit attributable to the parent company was 22.23 million yuan, reflecting a year-on-year increase of 7.10% [1] - The net profit after deducting non-recurring gains and losses was 9.88 million yuan, showing a year-on-year decrease of 11.64% [1] Financial Performance - The company achieved an operating income of 704 million yuan, which is a 19.58% increase compared to the previous year [1] - The net profit attributable to the parent company reached 22.23 million yuan, up by 7.10% year-on-year [1] - The net profit after excluding non-recurring items was 9.88 million yuan, down 11.64% from the previous year [1] Market Strategy - The company has been focusing on enhancing market promotion efforts [1] - Sales of the tetanus vaccine have shown steady growth during the reporting period [1]